CLIRNET plans to expand globally and improve how medical knowledge is shared and used in practice
Analysts expect modest revenue growth but pressure on profitability in the March quarter
The company reported net revenue of SEK 13.5 million for the full year 2025
The acquisition adds VYKAT XR (diazoxide choline), the first FDA-approved therapy for hyperphagia in Prader-Willi syndrome (PWS), a rare genetic disorder, to Neurocrine’s portfolio
STADA will market and distribute two EMA approved biosimilars developed by CuraTeQ in select European Union territories
The acquisition of Biocare enhances Agilent’s pathology portfolio and reflects our strategy to drive long-term growth
Moderna will appeal to the Federal Circuit to assert that its government-contractor immunity limits liability under federal law
Acquisition expands Axol’s portfolio of iPSC-derived retinal organoid and retinal pigment epithelium (RPE) models
Chemicals delivered improved efficiency and optimal capacity utilization, with EBIT rising 37% YoY
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
Subscribe To Our Newsletter & Stay Updated
